Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.43 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.43 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20450604 | 1.00 | KMT2A (0.51) | KMT2APOLBNOD1PLA2G2CPLA2G10 | |
| SCHEMBL12674184 | 1.00 | KMT2A (0.51) | KMT2APOLBNOD1PLA2G2CPLA2G10 | |
| SCHEMBL20450548 | 1.00 | KMT2A (0.51) | KMT2APOLBNOD1PLA2G2CPLA2G10 | |
| SCHEMBL25445243 | 1.00 | KMT2A (0.51) | KMT2APOLBNOD1PLA2G2CPLA2G10 | |
| SCHEMBL20450549 | 1.00 | KMT2A (0.51) | KMT2APOLBNOD1PLA2G2CPLA2G10 | |
| SCHEMBL24817622 | 1.00 | KMT2A (0.51) | KMT2APOLBNOD1PLA2G2CPLA2G10 | |
| SCHEMBL17747011 | 1.00 | KMT2A (0.51) | KMT2APOLBNOD1PLA2G2CPLA2G10 | |
| SCHEMBL16538711 | 1.00 | KMT2A (0.51) | KMT2APOLBNOD1PLA2G2CPLA2G10 | |
| SCHEMBL22074686 | 1.00 | KMT2A (0.51) | KMT2APOLBNOD1PLA2G2CPLA2G10 | |
| SCHEMBL20450601 | 1.00 | KMT2A (0.51) | KMT2APOLBNOD1PLA2G2CPLA2G10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024134676-A1 | PROCESS FOR THE PREPARATION OF TIRZEPATIDE | DR. REDDY’S LABORATORIES LIMITED (IN) | 2024-06-27 | — | — | WO | disclosed |
| US-9150633-B2 | Insulin analogues with an acyl and alkylene glycol moiety | NOVO NORDISK A/S (DK) | 2015-10-06 | — | — | US | disclosed |
| EP-2178912-B1 | INSULIN ANALOGUES WITH AN ACYL AND AKLYLENE GLYCOL MOIETY | NOVO NORDISK AS (DK) | 2015-07-08 | — | — | EP | disclosed |
| EP-2708554-A1 | Insulin analogues with an acyl and alkylene glycol moiety | NOVO NORDISK A/S (DK) | 2014-03-19 | — | — | EP | disclosed |
| US-20110098440-A1 | Insulin Analogues with an Acyl and Alkylene Glycol Moiety | NOVO NORDISK A/S (DK) | 2011-04-28 | — | — | US | disclosed |
| EP-2178912-A1 | INSULIN ANALOGUES WITH AN ACYL AND AKLYLENE GLYCOL MOIETY | Novo Nordisk A/S (DK) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009022013-A1 | INSULIN ANALOGUES WITH AN ACYL AND AKLYLENE GLYCOL MOIETY | NOVO NORDISK A/S (DK) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098440-A1 | Insulin Analogues with an Acyl and Alkylene Glycol Moiety | IAPP, INSR, IGF1R | KMT2A 418/4885POLB 3744/4885NOD1 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.